The landscape of US drug pricing is undergoing a fundamental and multi-layered transformation, moving from a system of opaque, rebate-driven negotiations to one defined by transparent federal mandates and consumer-facing benchmarks. For hospital and health system leaders, this shift is no longer a theoretical future risk but an immediate operational reality, as pharmacy economics are being recalibrated in real time through statute, voluntary agreements, and proposed federal payment models.
Expansion of federal pricing authority: The most durable change stems from the Inflation Reduction Act (IRA), with the first 10 Medicare-negotiated drug prices now in effect [1]. This authority is expanding rapidly, with new price cuts for 15 additional Part D drugs—representing US$42.5 billion in annual spending—scheduled for 2027, and negotiations set to include high-cost Part B physician-administered drugs by 2028. Running parallel to this congressionally mandated programme is an aggressive push toward ‘most-favored-nation’ (MFN) pricing [2]. A majority of major drug manufacturers have signed voluntary agreements tying drug prices to lower international benchmarks, primarily for Medicaid and cash-paying consumers. More consequentially, the administration has proposed two major demonstration models, GLOBE and GUARD, which would apply international reference pricing directly within Medicare Part B and Part D, a move expected to face significant legal challenges.
Direct-to-Consumer pricing as a public benchmark: This new pricing architecture is being made visible to the public through platforms like TrumpRx.gov, which lists brand-name drugs at federally backed, internationally benchmarked cash prices [3]. The integration of these discount cards into national retail chains, such as CVS, embeds these federal prices directly into the consumer market, establishing a visible cash benchmark that coexists with, and often undercuts, traditional negotiated rates. Simultaneously, expanded federal transparency mandates are forcing hospitals and payers to publish increasingly detailed pricing data, making the market more comparable and transparent than ever before.
PBM reform moves into enforcement mode: After years of scrutiny, oversight of Pharmacy Benefit Managers (PBMs) has shifted decisively into active enforcement. A landmark FTC settlement with a major PBM mandates sweeping changes, including delinking compensation from drug prices and increasing transparency [4]. This federal action is being reinforced by new state laws and proposed Department of Labor rules targeting PBM contracts with self-insured employers, creating a multi-dimensional regulatory environment.
Acceleration of retail competition: The competitive landscape is being reshaped by retail giants. Amazon’s expansion of same-day delivery and subscription models, alongside CVS’s integration of federal discount programmes, highlights a decisive industry shift toward convenience and transparent pricing [5]. This model stands in stark contrast to the care-integrated, but less consumer-flexible, model of hospital-based pharmacies, putting pressure on health systems to adapt.
For health systems, this confluence of forces means navigating a market with clearer boundaries and far less insulation. Heading into 2027, the strategic question is no longer whether this disruption will continue, but how effectively pharmacy operations, specialty margins, and outpatient growth strategies can be realigned to thrive in an environment where pricing authority is more visible, more tightly regulated, and increasingly shaped by direct-to-consumer benchmarks.
Related articles
President Trump issues executive order to lower drug prices
PBM practices lead US consumers to overpay for generics by 20%
References
1. GaBI Online - Generics and Biosimilars Initiative. Second wave of drugs selected for Medicare price negotiation [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Mar 23]. Available from: www.gabionline.net/policies-legislation/second-wave-of-drugs-selected-for-medicare-price-negotiation
2. GaBI Online - Generics and Biosimilars Initiative. US EO: delivering Most-Favored-Nation Prescription Drug Pricing to American patients [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Mar 23]. Available from: www.gabionline.net/policies-legislation/second-wave-of-drugs-selected-for-medicare-price-negotiation
3. GaBI Online - Generics and Biosimilars Initiative. Direct-to-Consumer TrumpRx aims to slash US drug prices [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Mar 23]. Available from: www.gabionline.net/pharma-news/direct-to-consumer-trumprx-aims-to-slash-us-drug-prices
4. GaBI Online - Generics and Biosimilars Initiative. FTC reveals extent of PBM drug mark-ups and profits [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Mar 23]. Available from: www.gabionline.net/pharma-news/direct-to-consumer-trumprx-aims-to-slash-us-drug-prices
5. GaBI Online - Generics and Biosimilars Initiative. Boehringer and GoodRx make Humira biosimilar available at 92% discount [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Mar 23]. Available from: www.gabionline.net/biosimilars/general/boehringer-and-goodrx-make-humira-biosimilar-available-at-92-discount
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2026 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment